Wang J, Dunn A J
Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport 71103, USA.
Neurochem Int. 1998 Aug;33(2):143-54. doi: 10.1016/s0197-0186(98)00016-3.
Neuroendocrine and neurochemical responses were studied following administration of recombinant mouse IL-6 (mIL-6) to mice. Intravenous (iv) or intraperitoneal (ip) injection of mIL-6 caused a rapid and short-lived activation of the hypothalamo-pituitary-adrenocortical (HPA) axis, as indicated by increases in plasma ACTH and corticosterone, with peak responses around 30-60 min. These responses contrast with those to ip mIL-1beta which is substantially more potent and induces a greater response which does not peak until about 2 h following ip administration. Unlike IL-1 and lipopolysaccharide (LPS), IL-6 had no detectable effect on norepinephrine metabolism. However, tryptophan concentrations were elevated in most brain regions studied 1-2 h following iv mIL-6, and 2 h following ip mIL-6, significantly later than the peak HPA response. 5-hydroxyindoleacetic acid (5-HIAA) and the ratio of 5-HIAA to serotonin (5-HT) were elevated at around the same time in the brain stem, and occasionally in other brain regions. These responses were observed at doses of mIL-6 as low as 0.25 microg, and near maximal effects were achieved by 0.5 microg. Recombinant human IL-6 elicited similar responses, but was significantly less potent. Heat-treated mIL-6 elicited none of the responses. Serum amyloid A protein (SAA) concentrations were not elevated until 4 h after iv or ip mIL-6 administration, suggesting that the neuroendocrine and neurochemical changes were not secondary to an acute phase protein response. Intracerebroventricular injection of mIL-6 also elevated tryptophan and 5-HIAA in the hypothalamus and brain stem. Pretreatment of mice with the cyclooxygenase inhibitor, indomethacin, or the nitric oxide synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME) did not attenuate the mIL-6 induced neuroendocrine or neurochemical responses. However, the ganglionic blocking drug, chlorisondamine, prevented the increases in tryptophan and 5-HIAA:5-HT ratios. IL-6 may contribute to the HPA and indoleaminergic responses to LPS and IL-1. It is possible that the increases of tryptophan and serotonin metabolism may contribute to some of the biological effects of IL-6.
在给小鼠注射重组小鼠白细胞介素-6(mIL-6)后,对其神经内分泌和神经化学应答进行了研究。静脉注射(iv)或腹腔注射(ip)mIL-6会导致下丘脑-垂体-肾上腺皮质(HPA)轴迅速且短暂地激活,表现为血浆促肾上腺皮质激素(ACTH)和皮质酮增加,峰值应答出现在30 - 60分钟左右。这些应答与腹腔注射mIL-1β的应答形成对比,mIL-1β的效力更强,诱导的应答更大,直到腹腔注射后约2小时才达到峰值。与白细胞介素-1(IL-1)和脂多糖(LPS)不同,IL-6对去甲肾上腺素代谢没有可检测到的影响。然而,在静脉注射mIL-6后1 - 2小时以及腹腔注射mIL-6后2小时,所研究的大多数脑区色氨酸浓度升高,明显晚于HPA应答峰值。5-羟吲哚乙酸(5-HIAA)以及5-HIAA与血清素(5-HT)的比值在脑干中大约同时升高,其他脑区偶尔也会升高。在低至0.25微克的mIL-6剂量下即可观察到这些应答,0.5微克时达到接近最大效应。重组人IL-6引发类似应答,但效力明显较低。经热处理的mIL-6未引发任何应答。血清淀粉样蛋白A(SAA)浓度直到静脉注射或腹腔注射mIL-6后4小时才升高,这表明神经内分泌和神经化学变化并非继发于急性期蛋白应答。脑室内注射mIL-6也会使下丘脑和脑干中的色氨酸和5-HIAA升高。用环氧化酶抑制剂吲哚美辛或一氧化氮合酶抑制剂N-ω-硝基-L-精氨酸甲酯(L-NAME)对小鼠进行预处理,并未减弱mIL-6诱导的神经内分泌或神经化学应答。然而,神经节阻断药物氯异吲哚胺可阻止色氨酸和5-HIAA:5-HT比值升高。IL-6可能参与了对LPS和IL-1的HPA和吲哚胺能应答。色氨酸和血清素代谢的增加可能在一定程度上促成了IL-6的某些生物学效应。